BECTON DICKINSON and CO

BDX’s Q2 2026 report shows steady revenue, strong margins, and a spin‑off that fuels share buybacks and debt cuts—boosting cash, liquidity, and growth prospects.

BD’s Q3 FY2026 earnings show modest yet steady growth—$5B revenue, 5% YoY rise, and 44% free cash‑flow jump—underscoring its focused strategy and resilience in a shifting reimbursement landscape.

BD’s Brazil partnership boosts semaglutide access, cuts costs, and fuels $120 M revenue, while quarterly dividends and Rule 144 compliance reinforce investor confidence.

BD’s FY 2026 Q3 results webcast reveals how AI‑driven diagnostics, trade‑policy impacts and competitive pressures shape the company’s margins, market share and growth strategy.

BDX insider trade shows confidence in its value‑based diagnostics strategy—boosting patient outcomes while keeping costs down and attracting investors.

Insider trading at Becton, Dickinson (BDX) shows routine, plan‑based sales with no market impact, yet offers insight into RSU timing, governance, and digital health strategy.